These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 23684836)

  • 1. Developing Countries Vaccine Manufacturers Network (DCVMN): engaging to step up for vaccine discovery and access. Meeting report 2012.
    Pagliusi S; Makhoana M; Datla M; Leite L; Hendriks J; Gholami A; Huang W; Gao Y; Jadhav S; Harshavardhan GV; Wu Y; Suhardono M; Homma A
    Vaccine; 2013 Jun; 31(31):3111-5. PubMed ID: 23684836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing Countries Vaccine Manufacturers Network: doing good by making high-quality vaccines affordable for all.
    Pagliusi S; Leite LC; Datla M; Makhoana M; Gao Y; Suhardono M; Jadhav S; Harshavardhan GV; Homma A
    Vaccine; 2013 Apr; 31 Suppl 2():B176-83. PubMed ID: 23598479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality vaccines for all people: Report on the 16th annual general meeting of the Developing Countries Vaccine Manufacturers' Network, 05-07th October 2015, Bangkok, Thailand.
    Pagliusi S; Ting CC; Khomvilai S;
    Vaccine; 2016 Jun; 34(31):3562-7. PubMed ID: 26947496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Better vaccines for healthier life. Part I. Conference report of the DCVMN International 14th Annual General Meeting Hanoi, Vietnam.
    Pagliusi S; Rustan R; Huang W; Nguyen T;
    Vaccine; 2014 Nov; 32(48):6325-9. PubMed ID: 24923636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.
    Jadhav S; Datla M; Kreeftenberg H; Hendriks J
    Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The art of partnerships for vaccines.
    Pagliusi S; Che Y; Dong S
    Vaccine; 2019 Sep; 37(40):5909-5919. PubMed ID: 31447125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices.
    Jadhav S; Gautam M; Gairola S
    Clin Microbiol Infect; 2014 May; 20 Suppl 5():37-44. PubMed ID: 24476201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccines, our shared responsibility.
    Pagliusi S; Jain R; Suri RK;
    Vaccine; 2015 May; 33(19):2197-2202. PubMed ID: 25749248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Better vaccines for healthier life. Part II. Conference report of the DCVMN International 14th Annual General Meeting Hanoi, Vietnam.
    Pagliusi S; Tippoo P; Sivaramakrishnan V; Nguyen T;
    Vaccine; 2014 Nov; 32(48):6330-5. PubMed ID: 24923638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines, inspiring innovation in health.
    Pagliusi S; Dennehy M; Kim H;
    Vaccine; 2018 Nov; 36(48):7430-7437. PubMed ID: 29789241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines: Shaping global health.
    Pagliusi S; Ting CC; Lobos F;
    Vaccine; 2017 Mar; 35(12):1579-1585. PubMed ID: 28237501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines: New challenges, new paradigms, new opportunities: Report of the 22nd DCVMN Annual General Meeting.
    Kumar Suri R; Hayman B; Prasad SD; Makhoana M; Tippoo P
    Vaccine; 2022 Jun; 40(26):3495-3505. PubMed ID: 35577632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging markets & emerging needs: developing countries vaccine manufacturers' perspective & its current status.
    Jadhav SS; Gautam M; Gairola S
    Biologicals; 2009 Jun; 37(3):165-8. PubMed ID: 19328010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Improving global access to new vaccines: intellectual property, technology transfer, and regulatory pathways].
    Crager SE
    Rev Panam Salud Publica; 2015 Jan; 37(1):59-68. PubMed ID: 25791189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing-country vaccine manufacturers' technical capabilities can make a difference in global immunization.
    Hayman B; Dennehy M
    Vaccine; 2021 Aug; 39(36):5153-5161. PubMed ID: 34362602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report.
    Pagliusi S; Hayman B; Jarrett S
    Vaccine; 2021 Apr; 39(18):2479-2488. PubMed ID: 33838948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Technology transfer in human vaccinology: a retrospective review on public sector contributions in a privatizing science field.
    Hendriks J
    Vaccine; 2012 Sep; 30(44):6230-40. PubMed ID: 22902679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccinology capacity building in Europe for innovative platforms serving emerging markets.
    Hendriks J; Holleman M; Hamidi A; Beurret M; Boog C
    Hum Vaccin Immunother; 2013 Apr; 9(4):932-6. PubMed ID: 23563518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Access to vaccine technologies in developing countries: Brazil and India.
    Milstien JB; Gaulé P; Kaddar M
    Vaccine; 2007 Nov; 25(44):7610-9. PubMed ID: 17913312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.